Status:
COMPLETED
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Lead Sponsor:
Groupe Hospitalier Pitie-Salpetriere
Conditions:
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-75 years
Brief Summary
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied. The objective of the CERADIAB study is to compare plasm...
Detailed Description
Sphingolipids represent a major class of lipids that are structural and signaling molecules. Major bioactive sphingolipids include ceramide, dihydroceramide, sphingosine, sphingosine-1-phosphate and s...
Eligibility Criteria
Inclusion
- type 1 or 2 diabetes
Exclusion
- atypical diabetes
- family dyslipidemia
- nonmetabolic hepatopathy
- severe renal failure
- corticosteroid or immunosuppressive therapy
Key Trial Info
Start Date :
April 4 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 16 2017
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT03447964
Start Date
April 4 2017
End Date
September 16 2017
Last Update
October 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Pitié-Salpêtrière
Paris, France, 75013